About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Report Type
Organization
Disposition
Year
Month
Found 72808 record(s)
Req # A-2019-001554
Adverse Reaction Report (AER) for Pms-carbamazepine. Report number: 000721643, 000722217. AER for Pms-zopiclone. Report number: E2B_02105402. AER for Pms-mirtazapine. Report number: E2B_01617063.Organization: Health Canada
July 2020
Req # A-2019-001649
Adverse Reaction Report (AER) for IRBESARTAN. Report numbers: 000721010, 000721884, 000721916, 000723435, E2B_02575844, E2B_02318610, E2B_02589614.Organization: Health Canada
July 2020
Req # A-2019-001725
Adverse Reaction Report (AER) for Vyvanse. Report numbers: 000727968, 000728288, E2B_02746123.Organization: Health Canada
July 2020
Req # A-2019-001897
Adverse Reaction Report (AER) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02298877, E2B_02460070, E2B_02467631, E2B_02476898, E2B_02482722, E2B_02483004, E2B_02483397, E2B_02479845, E2B_02485563, E2B_02449914, E2B_00945396, E2B_02457975,…Organization: Health Canada
July 2020
Req # A-2019-001905
Adverse Reaction Report (AER) for LEFLUNOMIDE. Report numbers: E2B_01722601, E2B_02318532, E2B_02411397, E2B_02392050, E2B_02389137, E2B_02393964, E2B_02387880, E2B_02386871, E2B_02390184, E2B_02423333, E2B_02423378, E2B_02424013, E2B_02424811,…Organization: Health Canada
July 2020
Req # A-2019-001951
Adverse Reaction Report (AER). Report numbers: E2B_02061972, E2B_02332998, E2B_02317541, E2B_02318615.Organization: Health Canada
July 2020
Req # A-2019-001993
Adverse Reaction Report (AER). Report numbers: 000723619, 000686654, 000718517, E2B_02263739, 000725234.Organization: Health Canada
July 2020
Req # A-2019-001995
Adverse Reaction Report (AER). Report numbers: E2B_02822474, E2B_02825081, E2B_02833866, E2B_02856321, E2B_02856394, E2B_02861087, E2B_02833866.Organization: Health Canada
July 2020
Req # A-2019-002029
Adverse Reaction Report (AER). Report number: 000732990.Organization: Health Canada
July 2020
Req # A-2019-002068
Adverse Reaction Report (AER) for TECTA. Report numbers: E2B_02885410, E2B_02872807.Organization: Health Canada
July 2020